In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap biotech stocks. The biotechnology sector is expanding quickly due to rising ...

Investors in Arvinas Inc (Symbol: ARVN) saw new options become available today, for the March 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

Below is a chart showing JBLU's trailing twelve month trading history, with the $6 strike highlighted in orange: And Arvinas Inc (Symbol: ARVN) saw options trading volume of 6,206 contracts ...

Results from clinical trials that wrap up soon could soon push shares of Recursion Pharmaceuticals (NASDAQ: RXRX), and Arvinas (NASDAQ: ARVN) through the roof. Before you get excited and fill your ...

Barclays analyst Peter Lawson maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) today and set a price target of $48.00. The company’s shares closed yesterday at $19.74.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arvinas Holding Company (ARVN – Research Report) and VolitionRX (VNRX – Research Report). Arvinas Holding ...

Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that ...